Circulating thrombomodulin during radiation therapy of lung cancer

Martin Hauer-Jensen, Feng Ming Kong, Louis M. Fink, Mitchell S. Anscher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation. The present study measured plasma TM in 17 patients before, during, and after radiation therapy of lung cancer: nine patients developed radiation pneumonitis, whereas eight matched patients did not. Plasma TM did not change significantly in patients who developed radiation pneumonitis. In contrast, patients who did not develop pneumonitis exhibited a moderate, but statistically significant, decrease in plasma TM antigen during the initial 1-2 weeks, with complete normalization towards the end of treatment. Our study suggests that decreased release of TM during the early phase of radiation therapy may be associated with reduced pulmonary toxicity. The use of plasma TM as a marker of pulmonary toxicity needs further study.

Original languageEnglish (US)
Pages (from-to)238-242
Number of pages5
JournalRadiation Oncology Investigations
Volume7
Issue number4
DOIs
StatePublished - Sep 20 1999

Fingerprint

Thrombomodulin
lungs
radiation therapy
Lung Neoplasms
Radiotherapy
cancer
Radiation Pneumonitis
toxicity
anticoagulants
antigens
radiation
ionizing radiation
markers
Lung
Ionizing Radiation
Anticoagulants
Pneumonia
Glycoproteins
Down-Regulation
Endothelial Cells

Keywords

  • Lung cancer
  • Radiation injuries
  • Radiation pneumonitis
  • Thrombomodulin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Circulating thrombomodulin during radiation therapy of lung cancer. / Hauer-Jensen, Martin; Kong, Feng Ming; Fink, Louis M.; Anscher, Mitchell S.

In: Radiation Oncology Investigations, Vol. 7, No. 4, 20.09.1999, p. 238-242.

Research output: Contribution to journalArticle

Hauer-Jensen, Martin ; Kong, Feng Ming ; Fink, Louis M. ; Anscher, Mitchell S. / Circulating thrombomodulin during radiation therapy of lung cancer. In: Radiation Oncology Investigations. 1999 ; Vol. 7, No. 4. pp. 238-242.
@article{c0c68a9d6749426eba15fcfa25e16df2,
title = "Circulating thrombomodulin during radiation therapy of lung cancer",
abstract = "The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation. The present study measured plasma TM in 17 patients before, during, and after radiation therapy of lung cancer: nine patients developed radiation pneumonitis, whereas eight matched patients did not. Plasma TM did not change significantly in patients who developed radiation pneumonitis. In contrast, patients who did not develop pneumonitis exhibited a moderate, but statistically significant, decrease in plasma TM antigen during the initial 1-2 weeks, with complete normalization towards the end of treatment. Our study suggests that decreased release of TM during the early phase of radiation therapy may be associated with reduced pulmonary toxicity. The use of plasma TM as a marker of pulmonary toxicity needs further study.",
keywords = "Lung cancer, Radiation injuries, Radiation pneumonitis, Thrombomodulin",
author = "Martin Hauer-Jensen and Kong, {Feng Ming} and Fink, {Louis M.} and Anscher, {Mitchell S.}",
year = "1999",
month = "9",
day = "20",
doi = "10.1002/(SICI)1520-6823(1999)7:4<238::AID-ROI5>3.0.CO;2-4",
language = "English (US)",
volume = "7",
pages = "238--242",
journal = "Radiation Oncology Investigations",
issn = "1065-7541",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Circulating thrombomodulin during radiation therapy of lung cancer

AU - Hauer-Jensen, Martin

AU - Kong, Feng Ming

AU - Fink, Louis M.

AU - Anscher, Mitchell S.

PY - 1999/9/20

Y1 - 1999/9/20

N2 - The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation. The present study measured plasma TM in 17 patients before, during, and after radiation therapy of lung cancer: nine patients developed radiation pneumonitis, whereas eight matched patients did not. Plasma TM did not change significantly in patients who developed radiation pneumonitis. In contrast, patients who did not develop pneumonitis exhibited a moderate, but statistically significant, decrease in plasma TM antigen during the initial 1-2 weeks, with complete normalization towards the end of treatment. Our study suggests that decreased release of TM during the early phase of radiation therapy may be associated with reduced pulmonary toxicity. The use of plasma TM as a marker of pulmonary toxicity needs further study.

AB - The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation. The present study measured plasma TM in 17 patients before, during, and after radiation therapy of lung cancer: nine patients developed radiation pneumonitis, whereas eight matched patients did not. Plasma TM did not change significantly in patients who developed radiation pneumonitis. In contrast, patients who did not develop pneumonitis exhibited a moderate, but statistically significant, decrease in plasma TM antigen during the initial 1-2 weeks, with complete normalization towards the end of treatment. Our study suggests that decreased release of TM during the early phase of radiation therapy may be associated with reduced pulmonary toxicity. The use of plasma TM as a marker of pulmonary toxicity needs further study.

KW - Lung cancer

KW - Radiation injuries

KW - Radiation pneumonitis

KW - Thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=0032886591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032886591&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6823(1999)7:4<238::AID-ROI5>3.0.CO;2-4

DO - 10.1002/(SICI)1520-6823(1999)7:4<238::AID-ROI5>3.0.CO;2-4

M3 - Article

VL - 7

SP - 238

EP - 242

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

SN - 1065-7541

IS - 4

ER -